Daniela Olivera Mesa

Daniela Olivera Mesa

Auto-generated profile, based on publicly available information

Daniela Olivera Mesa

MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in Science
Verified
Journal Article
Open access
PDF file
PWPatrick G. T. Walker
Patrick G. T. Walker
CWCharles Whittaker
Charles Whittaker
OWOliver J. Watson
Oliver J. Watson
MBMarc Baguelin
Marc Baguelin
PWPeter Winskill
Peter Winskill
AGAzra C. Ghani
Azra C. Ghani
Global prospects for COVID-19 control: Lower-income countries have recognized the potential impact of coronavirus disease 2019 (COVID-19) from observing ongoing epidemics. Many have intervened quickly and early with measures to slow viral transmission, which may partly explain the low rates observed so far in these countries. Walker et al. calibrated a global model with country-specific data (see the Perspective by Metcalf et al. ). Despite the potentially protective effects of younger demographics, the closer intergenerational contact, limitations on health care facilities, and frequency of comorbidities in lower-income countries require sustained nonpharmaceutical interventions (NPIs) to avoid overwhelming health care capacity. As a result of strict NPIs, the protective effects of immunity will be reduced, and it will be important to improve testing capacity. Ensuring equitable provision of oxygen and—when they are ready—pharmaceutical interventions should be a global priority. Science , this issue p. 413 ; see also p. 368

10 February 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
DMDaniela Olivera Mesa
Daniela Olivera Mesa
AHAlexandra Hogan
Alexandra Hogan
OWOliver J. Watson
Oliver J. Watson
GCGiovanni D. Charles
Giovanni D. Charles
KHKatharina Hauck
Katharina Hauck
PWPeter Winskill
Peter Winskill
Background: Vaccine hesitancy – a delay in acceptance or refusal of vaccines despite availability – has the potential to threaten the successful roll-out of SARS-CoV-2 vaccines globally. In this study, we aim to understand the likely impact of vaccine hesitancy on the control of the COVID-19 pandemic. Methods: We modelled the potential impact of vaccine hesitancy on the control of the pandemic and the relaxation of non-pharmaceutical interventions (NPIs) by combining an epidemiological model of SARS-CoV-2 transmission with data on vaccine hesitancy from population surveys. Results: Our simulations suggest that the mortality over a 2-year period could be up to 7.6 times higher in countries with high vaccine hesitancy compared to an ideal vaccination uptake if NPIs are relaxed. Alternatively, high vaccine hesitancy could prolong the need for NPIs to remain in place. Conclusions: While vaccination is an individual choice, vaccine-hesitant individuals have a substantial impact on the pandemic trajectory, which may challenge current efforts to control COVID-19. In order to prevent such outcomes, addressing vaccine hesitancy with behavioural interventions is an important priority in the control of the COVID-19 pandemic.

19 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AHAlexandra B. Hogan
Alexandra B. Hogan
PDPatrick Doohan
Patrick Doohan
SWSean L. Wu
Sean L. Wu
DMDaniela Olivera Mesa
Daniela Olivera Mesa
JTJaspreet Toor
Jaspreet Toor
AGAzra C. Ghani
Azra C. Ghani
With the ongoing evolution of the SARS-CoV-2 virus updated vaccines may be needed. We fitted a model linking immunity levels and protection to vaccine effectiveness data from England for three vaccines (Oxford/AstraZeneca AZD1222, Pfizer-BioNTech BNT162b2, Moderna mRNA-1273) and two variants (Delta, Omicron). Our model reproduces the observed sustained protection against hospitalisation and death from the Omicron variant over the first six months following dose 3 with the ancestral vaccines but projects a gradual waning to moderate protection after 1 year. Switching the fourth dose to a variant-matched vaccine against Omicron BA.1/2 is projected to prevent nearly twice as many hospitalisations and deaths over a 1-year period compared to administering the ancestral vaccine. This result is sensitive to the degree to which immunogenicity data can be used to predict vaccine effectiveness and uncertainty regarding the impact that infection-induced immunity (not captured here) may play in modifying future vaccine effectiveness.

8 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JCJoseph D. Challenger
Joseph D. Challenger
DMDaniela Olivera Mesa
Daniela Olivera Mesa
DDDari Da
Dari Da
RYR. Serge Yerbanga
R. Serge Yerbanga
TLThierry Lefevre
Thierry Lefevre
TCThomas S. Churcher
Thomas S. Churcher
Transmission-blocking vaccines that interrupt malaria transmission from humans to mosquitoes are being tested in early clinical trials. The activity of such a vaccine is commonly evaluated using membrane-feeding assays. Understanding the field efficacy of such a vaccine requires knowledge of how heavily infected wild, naturally blood-fed mosquitoes are, as this indicates how difficult it will be to block transmission. Here we use data on naturally infected mosquitoes collected in Burkina Faso to translate the laboratory-estimated activity into an estimated activity in the field. A transmission dynamics model is then utilised to predict a transmission-blocking vaccine’s public health impact alongside existing interventions. The model suggests that school-aged children are an attractive population to target for vaccination. Benefits of vaccination are distributed across the population, averting the greatest number of cases in younger children. Utilising a transmission-blocking vaccine alongside existing interventions could have a substantial impact against malaria.

28 November 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
AHAlexandra Hogan
Alexandra Hogan
SWSean Wu
Sean Wu
JTJaspreet Toor
Jaspreet Toor
DMDaniela Olivera Mesa
Daniela Olivera Mesa
PDPatrick Doohan
Patrick Doohan
AGAzra C Ghani
Azra C Ghani
Background: Vaccines have reduced severe disease and death from Coronavirus Disease 2019 (COVID-19). However, with evidence of waning efficacy coupled with continued evolution of the virus, health programmes need to evaluate the requirement for regular booster doses, considering their impact and cost-effectiveness in the face of ongoing transmission and substantial infection-induced immunity. Methods and findings: We developed a combined immunological-transmission model parameterised with data on transmissibility, severity, and vaccine effectiveness. We simulated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccine rollout in characteristic global settings with different population age-structures, contact patterns, health system capacities, prior transmission, and vaccine uptake. We quantified the impact of future vaccine booster dose strategies with both ancestral and variant-adapted vaccine products, while considering the potential future emergence of new variants with modified transmission, immune escape, and severity properties. We found that regular boosting of the oldest age group (75+) is an efficient strategy, although large numbers of hospitalisations and deaths could be averted by extending vaccination to younger age groups. In countries with low vaccine coverage and high infection-derived immunity, boosting older at-risk groups was more effective than continuing primary vaccination into younger ages in our model. Our study is limited by uncertainty in key parameters, including the long-term durability of vaccine and infection-induced immunity as well as uncertainty in the future evolution of the virus. Conclusions: Our modelling suggests that regular boosting of the high-risk population remains an important tool to reduce morbidity and mortality from current and future SARS-CoV-2 variants. Our results suggest that focusing vaccination in the highest-risk cohorts will be the most efficient (and hence cost-effective) strategy to reduce morbidity and mortality.

29 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RSRichard J. Sheppard
Richard J. Sheppard
OWOliver J. Watson
Oliver J. Watson
RPRachel Pieciak
Rachel Pieciak
JLJames Lungu
James Lungu
GKGeoffrey Kwenda
Geoffrey Kwenda
CGChristopher J. Gill
Christopher J. Gill
Reported COVID-19 cases and associated mortality remain low in many sub-Saharan countries relative to global averages, but true impact is difficult to estimate given limitations around surveillance and mortality registration. In Lusaka, Zambia, burial registration and SARS-CoV-2 prevalence data during 2020 allow estimation of excess mortality and transmission. Relative to pre-pandemic patterns, we estimate age-dependent mortality increases, totalling 3212 excess deaths (95% CrI: 2104–4591), representing an 18.5% (95% CrI: 13.0–25.2%) increase relative to pre-pandemic levels. Using a dynamical model-based inferential framework, we find that these mortality patterns and SARS-CoV-2 prevalence data are in agreement with established COVID-19 severity estimates. Our results support hypotheses that COVID-19 impact in Lusaka during 2020 was consistent with COVID-19 epidemics elsewhere, without requiring exceptional explanations for low reported figures. For more equitable decision-making during future pandemics, barriers to ascertaining attributable mortality in low-income settings must be addressed and factored into discourse around reported impact differences.